Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Doxycycline Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP7 known ✓ | P09237 | 1/20 | 0.69 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.69 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 10/20 | 0.70 |
| ▸ | USP2 | O75604 | 6/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.69 |
| ▸ | MMP2 | P08253 | 1/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.69 |
| ▸ | RECQL | P46063 | 7/20 | 0.64 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 6/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doxycycline Anhydrous SCHEMBL6627427 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL12011108 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL9574618 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL12194961 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL7850301 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL2614206 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL16726317 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL2614979 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL20716693 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR | |
| Doxycycline Anhydrous SCHEMBL19270311 | 1.00 | TDP1 (0.70) | TDP1USP2HSD17B10HIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5194 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122080142-A | Polypeptide for cancer targeted therapy and corresponding drug/fluorescent dye conjugate thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260140124-A1 | PCOS STRATIFICATION | THE UNIVERSITY OF BIRMINGHAM (GB) | 2026-05-21 | — | — | US | claimed |
| EP-4007582-B1 | ANTIBIOTICS IN COMBINATION WITH PHOTODYNAMIC THERAPY FOR USE IN A METHOD OF ENHANCING THE ANTIMICROBIAL ACTION OF SYSTEMICALLY ADMINISTERED ANTIBIOTICS | KOITE HEALTH OY (FI) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102327-A1 | METHODS FOR COVALENTLY FUNCTIONALIZING SEMICONDUCTING SINGLE WALLED CARBON NANOTUBES AND USES THEREOF | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-15 | — | — | WO | claimed |
| EP-4740024-A1 | ENDOMETRIOSIS MARKERS AND METHODS OF DIAGNOSING ENDOMETRIOSIS | The University Court Of The University of Edinburgh (GB) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-3790536-B1 | NANOCONTAINERS FOR TRANSPORTING NONPOLAR, LIPOPHILIC SUBSTANCES SUCH AS ANTIBIOTICS | KARLSRUHER INST TECHNOLOGIE (DE) | 2026-04-22 | — | — | EP | claimed |
| US-20260103824-A1 | Compositions and Methods for Selectively Synthesizing Triple-indexed cDNA Libraries | UNIV ROCKEFELLER (US) | 2026-04-16 | — | — | US | claimed |
| US-20260102479-A1 | METHOD FOR THE PURIFICATION OF CAPSULAR POLYSACCHARIDES | BIOLOGICAL E LTD (IN) | 2026-04-16 | — | — | US | claimed |
| CN-100548305-C | Compound vibramycin injection for animals and preparation method thereof | JIANGXI NUCLEAR INDUSTRY TIAND (CN) | 2009-10-14 | — | — | CN | claimed |
| CN-101460059-A | Antimicrobial therapy for bacterial infections | UNIV CALIFORNIA (US) | 2009-06-17 | — | — | CN | claimed |
| CN-101406166-A | Segregated early weaning method of piglet | HENAN NEIXIANG MU YUAN BREED C (CN) | 2009-04-15 | — | — | CN | claimed |
| US-20080085866-A1 | METALLO-DESFERRIOXAMINE COMPLEXES AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | WASHINGTON, UNIVERSITY OF (US) | 2008-04-10 | — | — | US | claimed |
| CN-101062042-A | Compound vibramycin injection for animals and the preparing method thereof | JIANGXI NUCLEAR INDUSTRY TIAND (CN) | 2007-10-31 | — | — | CN | claimed |
| CN-1531394-A | Methods | 猪改良英国有限公司 | 2004-09-22 | — | — | CN | claimed |
| CN-1158921-C | Application of waste liquid after vibramycin extraction in soil sterilization and disinsection | 陈兴业 | 2004-07-28 | — | — | CN | claimed |
| EP-1239894-A1 | BONE GENERATING PRODUCT | Henogen S.A. (BE) | 2002-09-18 | — | — | EP | claimed |
| CN-1326678-A | Application of waste liquid after vibramycin extraction in soil sterilization and disinsection | CHEN XINGYE (CN) | 2001-12-19 | — | — | CN | claimed |
| WO-2001045760-A1 | BONE GENERATING PRODUCT | HENOGEN S.A. (BE) | 2001-06-28 | — | — | WO | claimed |